Interview with Sergio Duplan, CPO Head & Country President Mexico, Novartis…
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Address: Calzada de Tlalpan #1779, Colonia San Diego Churubusco, Mexico D.F.,Mexico
Tel: (55) 5420-8600
Web: http://www.novartis.com.mx/10ybrand/NOVARTIS_WEB_2009/Soft_Templates/index.html
In Mexico, the Novartis Group consists of Novartis Pharmaceuticals, Sandoz, OTC, CIBA Vision, Novartis Animal Health, and Novartis Vaccines and Diagnostics. More than 1,700 employees and more than $7 billion MXP sales revenue in 2011.
Novartis Pharmaceuticals (patented medicines), Sandoz (generic products), OTC (prescription free medicines), CIBA Vision (provider of high technology contact lenses and their care products), Novartis Animal Health (health care for pets and livestock) and Novartis Vaccines and Diagnostics (vaccines and clinical diagnostic products).
Carlos Garcia said in December 2009 that 6-8% of Novartis’ annual revenue comes from Latin America, and that the area is “one of the main growth engines for the company”.…
Lundbeck Mexico GM Oscar Parra discusses raising awareness of depression in Mexico, Lundbeck’s innovative treatments for depression and Alzheimer’s, and managing to navigate the country’s regulatory process to ultimately benefit…
Daniel Pardo Bejarano, CEO of BOMI Mexico, details the competitive advantages and the unique business approach that make BOMI the logistics partner of choice of the Mexican healthcare industry, while…
In light of the recently released OECD Reviews of Health Systems: Mexico 2016, Roberto Martinez, general director of the OECD Mexico Center for Latin America, reveals the OECD’s key findings…
Gabriel O’Shea, National Commissioner of Seguro Popular, on how the institute generates more efficient and transparent resource allocation across Mexico as the country prepares to implement medical service exchange among…
Francisco González, CEO of ProMéxico, the Mexican investment agency, describes the strengths of Mexico’s research and industrial base, untapped business opportunities in the pharmaceutical and healthcare sectors, and new export…
Javier Amtmann, the new president of AMIIF, the Mexican association of pharmaceutical innovators, reveals AMIIF’s strategic priorities and key areas of focus. As Chairman of the Board of Menarini Mexico,…
Xavier Valdez analyses the dynamics impacting the Mexican pharmaceutical market and explains why IMS Health is transforming itself to strengthen its position as the partner of choice for decision-makers throughout the…
The Mexican pharmaceutical market’s capacity to change dramatically in a short period of time means that both innovators and generics companies must think strategically and “play their cards right” in…
Patricia Ostrosky, general director of the Institute of Biomedical Research in Mexico, details current research subjects and calls for greater collaboration between Mexican universities and the pharmaceutical industry to bring…
Sandoz’s ambitious strategy in Mexico includes aggressive product launches in biosimilars and oncology, a heightened focus on the institutional market, and an awareness of inorganic growth opportunities. GM Mariano de…
For Cristóbal Thompson, Executive Director of AMIIF, health is a formidable measure of productivity and competitiveness that Mexico can no longer overlook if it is to sustain robust economic growth. He…
Tackling both obesity and diabetes is a primary objective of the National Academy of Medicine of Mexico and requires a holistic, multidisciplinary approach, according to Dr. Graue Wiechers, president of…
See our Cookie Privacy Policy Here
